Arcus Biosciences Inc
Company Profile
Business description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Contact
3928 Point Eden Way
HaywardCA94545
USAT: +1 510 694-6200
E: investorinfo@arcusbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
577
Stocks News & Analysis
stocks
Microsoft earnings: Strength in cloud, guidance mixed
stocks
Chart of the week: Small caps lagging
stocks
An impending merger just raised our fair value for this ASX retail giant
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,344.80 | 77.30 | -0.92% |
| CAC 40 | 7,350.37 | 77.99 | -1.05% |
| DAX 40 | 19,077.54 | 179.80 | -0.93% |
| Dow JONES (US) | 41,763.46 | 378.08 | -0.90% |
| FTSE 100 | 8,110.10 | 49.53 | -0.61% |
| HKSE | 20,317.33 | 63.31 | -0.31% |
| NASDAQ | 18,095.15 | 512.78 | -2.76% |
| Nikkei 225 | 39,081.25 | 196.14 | -0.50% |
| NZX 50 Index | 12,579.18 | 59.72 | -0.47% |
| S&P 500 | 5,705.45 | 108.22 | -1.86% |
| S&P/ASX 200 | 8,083.80 | 76.20 | -0.93% |
| SSE Composite Index | 3,279.82 | 13.59 | 0.42% |